Quick Answer
BIOLARGO, INC. reported Total Revenue of $516.2 thousand for fiscal year 2017.
BIOLARGO, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | — | — | — | — | — | — |
| Total Assets | $8.31M -20.9% |
$10.51M +28.1% |
$8.21M +68.9% |
$4.86M +60.7% |
$3.02M -38.8% |
$4.94M +36.5% |
| Cash and Equivalents | $3.88M +9.4% |
$3.55M +0.3% |
$3.54M +91.2% |
$1.85M +92.4% |
$962.0K +34.4% |
$716.0K +9.3% |
| Long-Term Debt | — | — | $289.0K +21.9% |
$237.0K +31.7% |
$180.0K -64.5% |
$507.0K -27.6% |
| Stockholders Equity | $4.04M -54.3% |
$8.85M +29.3% |
$6.84M +40.3% |
$4.88M +4.8% |
$4.65M +20.6% |
$3.86M +279.2% |
| R&D Expense | $2.59M -10.0% |
$2.88M +26.3% |
$2.28M +73.0% |
$1.32M -3.5% |
$1.37M +2.2% |
$1.34M -9.1% |
| Operating Income | -$14.86M -243.0% |
-$4.33M +5.4% |
-$4.58M +15.0% |
-$5.39M +20.5% |
-$6.78M +10.6% |
-$7.58M -13.2% |
| Gross Profit | $3.41M -56.6% |
$7.85M +27.6% |
$6.15M +115.4% |
$2.86M +159.0% |
$1.10M -10.2% |
$1.23M +34.1% |
| Shares Outstanding | — | — | 292.95M +5.2% |
278.46M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $172.0K | +6.0% | +72.1% |
| Net Income | June 30, 2015 | -$1.82M | -120.3% | -133.3% |
| Total Assets | September 30, 2025 | $9.13M | -11.4% | -27.0% |
| Cash and Equivalents | September 30, 2025 | $4.55M | +17.1% | +31.0% |
| Long-Term Debt | September 30, 2024 | $180.0K | -38.6% | -2.2% |
| Stockholders Equity | September 30, 2025 | $6.58M | -23.3% | -24.8% |
| R&D Expense | September 30, 2025 | $615.0K | -10.9% | +15.0% |
| Operating Income | September 30, 2025 | -$7.18M | -576.7% | -298.4% |
| Gross Profit | September 30, 2025 | $372.0K | -78.4% | -73.8% |
| Shares Outstanding | March 31, 2020 | 178.48M | — | +7.4% |
- BIOLARGO, INC. reported Total Revenue of $516.2 thousand for fiscal year 2017.
- BIOLARGO, INC. showed an increase of +83.6% in Total Revenue compared to the prior fiscal year.
- BIOLARGO, INC. reported Net Income of -$3.69 million for fiscal year 2014.
- BIOLARGO, INC. showed a decrease of -46.0% in Net Income compared to the prior fiscal year.
- BIOLARGO, INC. reported Total Assets of $8.31 million for fiscal year 2025.
- BIOLARGO, INC. showed a decrease of -20.9% in Total Assets compared to the prior fiscal year.
- BIOLARGO, INC. reported Cash and Equivalents of $3.88 million for fiscal year 2025.
- BIOLARGO, INC. showed an increase of +9.4% in Cash and Equivalents compared to the prior fiscal year.
- BIOLARGO, INC. reported Long-Term Debt of $289.0 thousand for fiscal year 2023.
- BIOLARGO, INC. showed an increase of +21.9% in Long-Term Debt compared to the prior fiscal year.
- BIOLARGO, INC. reported Stockholders Equity of $4.04 million for fiscal year 2025.
- BIOLARGO, INC. showed a decrease of -54.3% in Stockholders Equity compared to the prior fiscal year.
- BIOLARGO, INC. reported R&D Expense of $2.59 million for fiscal year 2025.
- BIOLARGO, INC. showed a decrease of -10.0% in R&D Expense compared to the prior fiscal year.
- BIOLARGO, INC. reported Operating Income of -$14.86 million for fiscal year 2025.
- BIOLARGO, INC. showed a decrease of -243.0% in Operating Income compared to the prior fiscal year.
- BIOLARGO, INC. reported Gross Profit of $3.41 million for fiscal year 2025.
- BIOLARGO, INC. showed a decrease of -56.6% in Gross Profit compared to the prior fiscal year.
- BIOLARGO, INC. reported Shares Outstanding of 292.95 million shares for fiscal year 2023.
- BIOLARGO, INC. showed an increase of +5.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: